EZH2 and neoplasm: Reports showed that EZH2 inhibitors, such as suberoylanilide hydroxamic acid (SAHA) and 3-deazaneplanocin A (DZNep), exerted anticancer effects through activation of tumor-suppressor microRNAs (miRNAs) in gastric and liver cancer cells27.